(40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP LIQUID

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Vedd Meg Most

Termékjellemzők Termékjellemzők (SPC)
10-12-2018

Aktív összetevők:

SODIUM CHLORIDE; POTASSIUM CHLORIDE

Beszerezhető a:

BAXTER CORPORATION

ATC-kód:

B05BB01

INN (nemzetközi neve):

ELECTROLYTES

Adagolás:

900MG; 300MG

Gyógyszerészeti forma:

LIQUID

Összetétel:

SODIUM CHLORIDE 900MG; POTASSIUM CHLORIDE 300MG

Az alkalmazás módja:

INTRAVENOUS

db csomag:

1000ML

Recept típusa:

Ethical

Terápiás terület:

REPLACEMENT PREPARATIONS

Termék összefoglaló:

Active ingredient group (AIG) number: 0213340002; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2012-12-10

Termékjellemzők

                                Potassium Chloride in 0.9% Sodium Chloride Injection, USP Prescribing
Information
_ _
_Page 1 of 15_
PRESCRIBING INFORMATION
POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION, USP
IN PLASTIC CONTAINER
VIAFLEX
Container
20mmol/L Potassium Chloride in Sodium in 0.9% Chloride Injection
40mmol/L Potassium Chloride in Sodium in 0.9% Chloride Injection
SOLUTION FOR INFUSION
Solutions Affecting the Electrolyte Balance
BAXTER CORPORATION
Mississauga, ON L5N 0C2
Date of Revision:
December 10, 2018
Control No. 221539
Potassium Chloride in 0.9% Sodium Chloride Injection, USP Prescribing
Information
_ _
_Page 2 of 15_
TABLE OF CONTENTS
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
INSTRUCTIONS FOR USE AND HANDLING AND DISPOSAL
................................11
DIRECTIONS FOR USE OF VIAFLEX PLUS PLASTIC CONTAINER
......................11
OVERDOSE
......................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
Potassium Chloride in 0.9% Sodium Chlo
                                
                                Olvassa el a teljes dokumentumot
                                
                            

Dokumentumok más nyelveken

Termékjellemzők Termékjellemzők francia 10-12-2018